Yoshiro Kato^*, Yoshikazu Naiki^†, Takayuki Komatsu^†, Kazuko Takahashi^†, Jiro Nakamura^*, Naoki Koide^†

Oncology Research, Vol.25, No.4, pp. 479-483, 2017, DOI:10.3727/096504016X14721731148893

Abstract A Wnt agonist, 2-amino-4-[3,4-(methylenedioxy)benzylamino]-6-(3-methoxyphenyl) pyrimidine, is a cellpermeable pyrimidine compound that has been shown to mimic the effect of Wnt. In this study, leukemic mouse cell lines, RAW 264.7 and J774.1, were incubated with the Wnt agonist. The Wnt agonist showed cell death in the concentration of 1–10 mM. The Wnt agonist did not show inhibition of GSK-3β activity but induced β-catenin accumulation in the nucleus. The Wnt agonist showed caspase-independent cell death, but no further involvement in cell death ER stress signaling. Here we discuss the possible mechanism of Wnt agonist-induced apoptotic cell death More >

Bingqian Ding¹, Bei Cui¹, Ming Gao, Zhenjiang Li, Chenyang Xu, Shaokang Fan, Weiya He

Oncology Research, Vol.25, No.3, pp. 331-340, 2017, DOI:10.3727/096504016X14736286083065

Abstract Ras-related protein 25 (Rab25) is a member of the Rab family, and it has been reported to play an important role in tumorigenesis. However, its direct involvement in human glioblastoma multiforme (GBM) is still unclear. The aim of the current study was to investigate the potential role of Rab25 in the growth, proliferation, invasion, and migration of human GBM. Our results showed that Rab25 expression was significantly higher in human GBM cell lines compared with a normal astrocyte cell line. In vitro functional studies revealed that knockdown of Rab25 reduced cell proliferation and inhibited invasion More >

Anne Riemann^*, Antje Güttler^†, Verena Haupt^*, Henri Wichmann^†, Sarah Reime^*, Matthias Bache^†, Dirk Vordermark^†, Oliver Thews^*

Oncology Research, Vol.26, No.2, pp. 191-200, 2018, DOI:10.3727/096504017X14965111926391

Abstract Carbonic anhydrase (CA) IX has emerged as a promising target for cancer therapy. It is highly upregulated in hypoxic regions and mediates pH regulation critical for tumor cell survival as well as extracellular acidification of the tumor microenvironment, which promotes tumor aggressiveness via various mechanisms, such as augmenting metastatic potential. Therefore, the aim of this study was to analyze the complex interdependency between CA IX and the tumor microenvironment in prostate tumor cells with regard to potential therapeutic implications. CA IX was upregulated by hypoxia as well as acidosis in prostate cancer cells. This induction… More >

SHAHID KARIM^1,*, ALANOUD NAHER ALGHANMI¹, MAHA JAMAL¹, HUDA ALKREATHY¹, ALAM JAMAL², HIND A. ALKHATABI³, MOHAMMED BAZUHAIR¹, AFTAB AHMAD^4,5

Oncology Research, Vol.32, No.5, pp. 817-830, 2024, DOI:10.32604/or.2024.048988

Abstract Cancer frequently develops resistance to the majority of chemotherapy treatments. This study aimed to examine the synergistic cytotoxic and antitumor effects of SGLT2 inhibitors, specifically Canagliflozin (CAN), Dapagliflozin (DAP), Empagliflozin (EMP), and Doxorubicin (DOX), using in vitro experimentation. The precise combination of CAN+DOX has been found to greatly enhance the cytotoxic effects of doxorubicin (DOX) in MCF-7 cells. Interestingly, it was shown that cancer cells exhibit an increased demand for glucose and ATP in order to support their growth. Notably, when these medications were combined with DOX, there was a considerable inhibition of glucose consumption, as More > Graphic Abstract

PRABHAT KUMAR, ANJANA SARKAR, PURNIMA JAIN^*

Journal of Polymer Materials, Vol.39, No.1-2, pp. 121-135, 2022, DOI:10.32381/JPM.2022.39.1-2.8

Abstract Biocompatible graphene derivative materials (GBMs) to harness the maximum potential of pristine graphene biologically, is the most important strategy for its advanced applications in pharmaceutical and other biomedical fields. Currently, scientists are trying to find this by using biopolymer nanocomposites or anchored materials. Nevertheless, tuning the bare GBMs towards biocompatibility is a beautiful approach to exploit the fundamental potential of pristine graphene vis-à-vis suppressing the effects of incorporated biopolymers or anchored materials. Herein, a large-scale, cost-effective, facile, and environment-friendly green synthetic strategy is used for the synthesis of reduced graphene oxide (rGO) nanosheet using L-ascorbic… More >

QIN YU^1,2,#, CHEN CHEN^4,5,#, HAIYAN ZHANG^6,#, JIN CHEN², JUNKANG SHEN^1,3,*, JUN YAN^5,*

BIOCELL, Vol.47, No.6, pp. 1279-1292, 2023, DOI:10.32604/biocell.2023.027553

Abstract Background: HLA-DMA presents pathogen-derived antigens to CD4+ and CD8+ T cells, respectively, and plays a significant part in initiating the immune response. So far, the impact of HLA expression on the prognosis of BC cells is controversial, because few studies have shown that the expressions of some HLA genes are related to the improvement of the survival rate. Up till now, however, the relationship between HLA-DMA and LUAD has not yet been assessed. Methods: We analyzed the TCGA database and assessed the prognostic value of HLA-DMA in LUAD. We conducted the Kruskal–Wallis and Wilcoxon signed-rank test… More >

YONGKANG SHI, JUN MA, KE CHEN, BIN CHEN^*

Oncology Research, Vol.30, No.4, pp. 201-210, 2022, DOI:10.32604/or.2022.027584

Abstract 5-Fluorouracil (5-FU) is a commonly used chemotherapeutic agent for various cancers. However, the drug resistance developed by tumor cells hinders the therapeutic effect. Konjac glucomannan (KGM) is indicated to sensitize 5-FU-resistant hepatocellular carcinoma (HCC) cells to 5-FU. In our study, we found that KGM or 5-FU treatment alone did not affect the malignant cell behaviors and endoplasmic reticulum (ER) stress of 5-FU-resistant HCC cells or HepG2/5-FU and Bel-7402/5-FU cells, while cotreatment with KGM and 5-FU significantly facilitated HCC cell apoptosis and ER stress and suppressed cell proliferation potential and migration abilities. Moreover, we explored the… More >

AHMED M. ELSHAZLY^1,2, TUONG VI V. NGUYEN¹, DAVID A. GEWIRTZ^1,*

Oncology Research, Vol.30, No.1, pp. 1-12, 2022, DOI:10.32604/or.2022.026459

Abstract PARP inhibitors have proven to be effective in conjunction with conventional therapeutics in the treatment of various solid as well as hematologic malignancies, particularly when the tumors are deficient in DNA repair pathways. However, as the case with other chemotherapeutic agents, their effectiveness is often compromised by the development of resistance. PARP inhibitors have consistently been reported to promote autophagy, a process that maintains cellular homeostasis and acts as an energy source by the degradation and reutilization of damaged subcellular organelles and proteins. Autophagy can exhibit different functional properties, the most prominent being cytoprotective. In More >

Wei Ni^*†‡, Lin Luo^*†‡, Ping Zuo^*†‡, Renping Li^*†‡, Xiaobing Xu^*†‡, Fan Wen^*†‡, Dong Hu^*†‡

Oncology Research, Vol.27, No.6, pp. 703-712, 2019, DOI:10.3727/096504018X15426775024905

Abstract Glioma is a commonly diagnosed brain tumor that shows high mortality rate. Despite the great advancement of cancer therapy in recent years, chemotherapy is still an important approach for treatment of glioma. However, long-term chemotherapy usually causes serious side effects or complications. It is desirable to take strategies to enhance the efficacy of current chemotherapy. In the present study, we observed obvious upregulation of miR-374a in glioma cells. More importantly, we found that knockdown of miR-374a was able to enhance the etoposide-induced cytotoxicity against glioma cells. Mechanically, we demonstrated that FOXO1 was the target of More >

Jing Tang^*1, Xu Yong Li^†1, Jing Bo Liang^‡, De Wu^§, Li Peng^¶, Xiaobing Li^¶

Oncology Research, Vol.27, No.6, pp. 635-641, 2019, DOI:10.3727/096504018X15288447760357

Abstract Apatinib is an oral TKI with antiangiogenic properties, and it is currently approved for the treatment of advanced gastric cancer in China. This agent has also been tested in other human solid tumors, including non-small cell lung cancer (NSCLC). Since the combination of chemotherapy and an antiangiogenic agent has been shown to be a feasible strategy in NSCLC, it is conceivable that a similar approach combining apatinib with chemotherapy may yield clinical activity. With this in mind, we investigated the efficiency of apatinib in combination with pemetrexed or docetaxel in advanced NSCLC. We treated a… More >